These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24103341)

  • 21. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.
    Dias MF; Joo K; Kemp JA; Fialho SL; da Silva Cunha A; Woo SJ; Kwon YJ
    Prog Retin Eye Res; 2018 Mar; 63():107-131. PubMed ID: 29097191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optogenetics-Mediated Gene Therapy for Retinal Diseases.
    Tomita H; Sugano E
    Adv Exp Med Biol; 2021; 1293():535-543. PubMed ID: 33398840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early therapeutic trials for retinitis pigmentosa].
    Dufier JL
    Bull Acad Natl Med; 2003; 187(9):1685-92; discussion 1692-4. PubMed ID: 15369238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular-physiological aspects of peptide regulation of function of the retina in retinitis pigmentosa].
    Khavinson VKh; Proniaeva VE; Lin'kova NS; Trofimova SV; Umnpv RS
    Fiziol Cheloveka; 2014; 40(1):129-34. PubMed ID: 25272779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal models and different therapies for treatment of retinitis pigmentosa.
    Rivas MA; Vecino E
    Histol Histopathol; 2009 Oct; 24(10):1295-322. PubMed ID: 19688697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration of Vision and Retinal Responses After Adeno-Associated Virus-Mediated Optogenetic Therapy in Blind Dogs.
    Nikonov S; Aravand P; Lyubarsky A; Nikonov R; Luo AJ; Wei Z; Maguire AM; Phelps NT; Shpylchak I; Willett K; Aleman TS; Huckfeldt RM; Ramachandran PS; Bennett J
    Transl Vis Sci Technol; 2022 May; 11(5):24. PubMed ID: 35604672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for expanding the operational range of channelrhodopsin in optogenetic vision.
    Mutter M; Münch TA
    PLoS One; 2013; 8(11):e81278. PubMed ID: 24312285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Modern approaches to the retinitis pigmentosa treatment in the older age patients (literature review).].
    Derkach AV; Trofimova SV
    Adv Gerontol; 2019; 32(6):1017-1022. PubMed ID: 32160443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoring the ON Switch in Blind Retinas: Opto-mGluR6, a Next-Generation, Cell-Tailored Optogenetic Tool.
    van Wyk M; Pielecka-Fortuna J; Löwel S; Kleinlogel S
    PLoS Biol; 2015 May; 13(5):e1002143. PubMed ID: 25950461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optogenetic Strategies for Vision Restoration.
    Lu Q; Pan ZH
    Adv Exp Med Biol; 2021; 1293():545-555. PubMed ID: 33398841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies.
    Liu W; Liu S; Li P; Yao K
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optogenetics and translational medicine.
    Chow BY; Boyden ES
    Sci Transl Med; 2013 Mar; 5(177):177ps5. PubMed ID: 23515075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinal prostheses: clinical results and future challenges.
    Picaud S; Sahel JA
    C R Biol; 2014 Mar; 337(3):214-22. PubMed ID: 24702848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention.
    Farrar GJ; Kenna PF; Humphries P
    EMBO J; 2002 Mar; 21(5):857-64. PubMed ID: 11867514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy and retinitis pigmentosa: advances and future challenges.
    Dejneka NS; Bennett J
    Bioessays; 2001 Jul; 23(7):662-8. PubMed ID: 11462220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optogenetic approaches to therapy for inherited retinal degenerations.
    De Silva SR; Moore AT
    J Physiol; 2022 Nov; 600(21):4623-4632. PubMed ID: 35908243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa.
    Schön C; Becirovic E; Biel M; Michalakis S
    Methods Mol Biol; 2018; 1715():33-46. PubMed ID: 29188504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene Correction Reverses Ciliopathy and Photoreceptor Loss in iPSC-Derived Retinal Organoids from Retinitis Pigmentosa Patients.
    Deng WL; Gao ML; Lei XL; Lv JN; Zhao H; He KW; Xia XX; Li LY; Chen YC; Li YP; Pan D; Xue T; Jin ZB
    Stem Cell Reports; 2018 Apr; 10(4):1267-1281. PubMed ID: 29526738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Let There Be Light: Gene and Cell Therapy for Blindness.
    Dalkara D; Goureau O; Marazova K; Sahel JA
    Hum Gene Ther; 2016 Feb; 27(2):134-47. PubMed ID: 26751519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optogenetic Stimulation for Restoring Vision to Patients Suffering From Retinal Degenerative Diseases: Current Strategies and Future Directions.
    Montazeri L; El Zarif N; Trenholm S; Sawan M
    IEEE Trans Biomed Circuits Syst; 2019 Dec; 13(6):1792-1807. PubMed ID: 31689206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.